Forte Biosciences (NASDAQ: FBRX) CFO receives new option and RSU awards

Rhea-AI Filing Summary

Forte Biosciences reported that its Chief Financial Officer, Riley Antony A, received new equity awards effective January 12, 2026. The awards include a stock option covering 90,000 shares of common stock with an exercise price of $29.66 per share and an expiration date of January 12, 2036, and a grant of 60,000 restricted stock units (RSUs).

The option vests monthly, with one forty-eighth of the total option shares vesting each month starting from a vesting commencement date of January 1, 2026, so that the option is fully vested after four years. The RSUs vest annually, with one fourth of the total RSUs vesting on each anniversary of the same January 1, 2026 vesting commencement date, resulting in full vesting over four years, assuming the CFO continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riley Antony A

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$29.66	01/12/2026		A		90,000		(1)	01/12/2036	Common Stock	90,000	$0	90,000	D
Restricted Stock Units	(2)	01/12/2026		A		60,000		(3)	(3)	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Forte Biosciences (FBRX) report for its CFO on January 12, 2026?

Forte Biosciences reported that its Chief Financial Officer, Riley Antony A, was granted a stock option for 90,000 shares of common stock and 60,000 restricted stock units (RSUs), both effective January 12, 2026.

What are the terms of the Forte Biosciences CFO stock option grant reported in this Form 4?

The CFO received a stock option covering 90,000 shares of Forte Biosciences common stock at an exercise price of $29.66 per share, expiring on January 12, 2036. The option vests monthly, with one forty-eighth of the total shares vesting each month starting from a vesting commencement date of January 1, 2026, and becomes fully vested after four years, subject to continued service.

How do the Forte Biosciences (FBRX) RSUs granted to the CFO vest?

The CFO’s award of 60,000 RSUs vests over four years. One fourth of the total RSUs vests annually on each anniversary of the January 1, 2026 vesting commencement date, so that all RSUs are fully vested on the four-year anniversary, assuming the CFO continues as a Service Provider under the 2021 Equity Incentive Plan.

What does each Forte Biosciences RSU granted to the CFO represent?

Each restricted stock unit, or RSU, granted to the CFO represents a contingent right to receive one share of Forte Biosciences, Inc. common stock, subject to the vesting conditions described in the award terms.

Is the Forte Biosciences CFO’s ownership reported as direct or indirect in this Form 4?

The Form 4 reports the CFO’s holdings in these derivative securities as direct ownership. After the reported grants, the CFO beneficially owns 90,000 stock options and 60,000 RSUs, all held directly.

What conditions apply to the vesting of the Forte Biosciences CFO’s equity awards?

The vesting of both the stock options and RSUs is conditioned on the CFO continuing to be a Service Provider, as defined in Forte Biosciences’ 2021 Equity Incentive Plan, through each applicable vesting date. If service ends, unvested portions may not vest.